These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8989224)

  • 1. Depot somatostatin analogs--a new first line therapy for acromegaly.
    Robbins RJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):15-7. PubMed ID: 8989224
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lanreotide++: a new therapeutic option in acromegaly].
    Díez JJ
    Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
    [No Abstract]   [Full Text] [Related]  

  • 4. Somatuline LA: a new treatment for acromegaly.
    Bouloux PM
    Hosp Med; 1998 Aug; 59(8):642-5. PubMed ID: 9829060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pregnancy in an acromegalic patient treated with lanreotide and bromocryptin].
    Sánchez R; Boix E; del Pino Navarro M; Picó A
    Med Clin (Barc); 1999 Jul; 113(5):198. PubMed ID: 10480146
    [No Abstract]   [Full Text] [Related]  

  • 6. New drugs: Maraviroc and Lanreotide.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(6):778-83. PubMed ID: 18032144
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
    Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
    J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of acromegaly with a new slow release somatostatin analog, lanreotide].
    Boucekkine C; Catus F; Blumberg-Tick J; Pholséna M; Chanson P; Schaison G
    Ann Endocrinol (Paris); 1994; 55(6):261-9. PubMed ID: 7864583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quality of life in acromegaly.
    Pantanetti P; Sonino N; Arnaldi G; Boscaro M
    J Endocrinol Invest; 2003; 26(8 Suppl):35-8. PubMed ID: 15233210
    [No Abstract]   [Full Text] [Related]  

  • 12. Lanreotide Autogel in the management of acromegaly.
    Molitch ME
    Drugs; 2008; 68(5):724. PubMed ID: 18370451
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
    Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
    Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incomplete analgesic effect of lanreotide in acromegaly.
    Maffei P; Martini C; Sicolo N
    Headache; 1997 May; 37(5):299-300. PubMed ID: 9195771
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors].
    Kanyinda-K JM; Samalin E; Sebah H; Gallix B; Ychou M
    Gastroenterol Clin Biol; 2008 Dec; 32(12):989-91. PubMed ID: 18945567
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medical treatment of acromegaly].
    Lorcy Y
    Ann Endocrinol (Paris); 2005 Feb; 66(1):55-8. PubMed ID: 15798597
    [No Abstract]   [Full Text] [Related]  

  • 18. [A new therapy for acromegaly].
    Beckers A; Stevenaert A; Hennen G
    Rev Med Liege; 1988 Jun; 43(11):429-32. PubMed ID: 2899902
    [No Abstract]   [Full Text] [Related]  

  • 19. Uneventful pregnancy in an acromegalic patient treated with slow-release lanreotide: a case report.
    de Menis E; Billeci D; Marton E; Gussoni G
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1489. PubMed ID: 10199803
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
    Drange MR; Melmed S
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.